{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:55:57Z","timestamp":1759730157037,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00471","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T07:47:44Z","timestamp":1595576864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Marilda","family":"Mormando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Puliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Barnabei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Lauretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonsina","family":"Chiefari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelangelo","family":"Russillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cognetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialuisa","family":"Appetecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1210\/jc.2003-030395","article-title":"Tumors metastatic to the pituitary gland: case report and literature review","volume":"89","author":"Komninos","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11102-010-0229-4","article-title":"Intracranial metastatic disease rarely involves the pituitary: retrospective analysis of 935 metastases in 155 patients and review of the literature","volume":"13","author":"Marsh","year":"2010","journal-title":"Pituitary."},{"key":"B3","article-title":"Metastatic spread to the pituitary","volume-title":"Neuroendocrinology.","author":"Shimon","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1227\/00006123-198712000-00030","article-title":"Metastatic tumor of the pituitary gland","volume":"21","author":"Nelson","year":"1987","journal-title":"Neurosurgery."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1530\/EC-18-0338","article-title":"Pituitary metastasis: a rare condition","volume":"7","author":"Javanbakht","year":"2018","journal-title":"Endocr Connect."},{"key":"B6","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/annonc\/mdp252","article-title":"Epidemiology of invasive cutaneous melanoma","volume":"20","author":"MacKie","year":"2009","journal-title":"Ann Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clindermatol.2008.09.001","article-title":"Melanoma epidemiology and trends","volume":"27","author":"Garbe","year":"2009","journal-title":"Clin Dermatol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch1","article-title":"Epidemiology of melanoma","volume-title":"Cutaneous Melanoma, Etiology and Therapy","author":"Matthews","year":"2017"},{"key":"B9","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin."},{"key":"B11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/00325481.2019.1569354","article-title":"Early and late relapses of cutaneous melanoma patients","volume":"131","author":"Tas","year":"2019","journal-title":"Postgrad Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3171\/jns.2003.99.5.0913","article-title":"Metastatic melanoma of the pituitary gland","volume":"99","author":"Leung","year":"2003","journal-title":"Case report. J Neurosurg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1017\/S0317167100006752","article-title":"Metastatic melanoma to the pituitary gland","volume":"34","author":"McCutcheon","year":"2007","journal-title":"Can J Neurol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2176\/nmc.cr2012-0068","article-title":"Pituitary apoplexy caused by hemorrhage from pituitary metastatic melanoma: case report","volume":"53","author":"Masui","year":"2013","journal-title":"Neurol Med Chir (Tokyo)."},{"key":"B15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-008-9785-0","article-title":"Multiple intracranial melanoma metastases: case report and review of the literature","volume":"93","author":"Guzel","year":"2009","journal-title":"J Neurooncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jocn.2010.07.111","article-title":"Melanoma of the sellar region","volume":"18","author":"Wang","year":"2011","journal-title":"J Clin Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e6483","DOI":"10.1097\/MD.0000000000006483","article-title":"Progressive visual disturbance and enlarging prolactinoma caused by melanoma metastasis: a case report and literature review","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine."},{"key":"B18","doi-asserted-by":"publisher","first-page":"115\u20136","DOI":"10.1111\/j.1750-3639.2007.00044_1.x","article-title":"A man in his mid-70s with a sellar mass","volume":"17","author":"Jung","year":"2007","journal-title":"Brain Pathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature."},{"key":"B20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3171\/2014.12.JNS14870","article-title":"Pituitary metastases: current practice in Japan","volume":"123","author":"Habu","year":"2015","journal-title":"J Neurosurg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11102-014-0552-2","article-title":"Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis","volume":"18","author":"He","year":"2015","journal-title":"Pituitary."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1634\/theoncologist.2019-0520","article-title":"Extended survival after surgical resection for pituitary metastases: clinical features, management, and outcomes of metastatic disease to the sella","volume":"25","author":"Patel","year":"2019","journal-title":"Oncologist."},{"key":"B23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3390\/cancers11121950","article-title":"Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review","volume":"11","author":"Greco","year":"2019","journal-title":"Cancers."},{"key":"B33","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol."},{"volume-title":"NCCN clinical practice guideline in oncology, cutaneous melanoma. Version 2.2020","year":"2020","author":"Network","key":"B34"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3390\/cancers11111642","article-title":"Efficacy, safety, and tolerability of approved combination BRAF and MEK inhibitor regimens for BRAF-mutant melanoma","volume":"11","author":"Hamid","year":"2019","journal-title":"Cancers."},{"key":"B36","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"212515","DOI":"10.7573\/dic.212515","article-title":"Treatment with combined dabrafenib and trametinib in BRAF(V600E)-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation","volume":"7","author":"Brugnara","year":"2018","journal-title":"Drugs Context."},{"key":"B38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1210\/er.2006-0042","article-title":"Pituitary tumor-transforming gene: physiology and implications for tumorigenesis","volume":"28","author":"Vlotides","year":"2007","journal-title":"Endocr Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"113472","DOI":"10.18632\/oncotarget.23052","article-title":"Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib","volume":"8","author":"Caporali","year":"2017","journal-title":"Oncotarget."},{"key":"B40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.tvjl.2018.08.012","article-title":"The mRNA expression of PTTG1 is a strong prognostic indicator for recurrence after hypophysectomy in dogs with corticotroph pituitary adenomas","volume":"240","author":"Vastenhout","year":"2018","journal-title":"Vet J."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T07:47:47Z","timestamp":1595576867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":40,"alternative-id":["10.3389\/fendo.2020.00471"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00471","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"article-number":"471"}}